CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million

Reuters

11/24

CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million

CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2585461140"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585461140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585461140?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585461140","market":"fut","top_or_hot":-1,"title":"CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-24 20:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持倉","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL6dTwrC:1","article_id":"2585461140","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585461140","pubTimestamp":1763986402,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CureVac NV reported a net profit of 273.2 million for the third quarter of 2025, down from 338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was 161.6 million, compared to 194.9 million in the prior-year period. The net financial result showed a loss of 2.6 million for the third quarter of 2025, compared to a gain of 2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were 1.21, compared to 1.51 and 1.50 respectively in 2024. For the first nine months, basic earnings per share were 0.72 and diluted earnings per share were 0.71, down from 0.87 and 0.86 in the previous year. Revenues were 54.1 million for the third quarter and 56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstandi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BNTX":"BioNTech SE","BK4588":"碎股","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓","CVAC":"CureVac B.V."},"translate_title":"CureVac NV报告第三季度净利润为2.732亿欧元，九个月净利润为1.616亿欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVAC":0.9,"BNTX":0.9},"content_text":"CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million\n    \n\n        CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}